Shares of Jazz rose more than 2% in pre-market today, likely due to the better-than-expected results. Year to date, the stock has gained 13% compared with the industry’s 7% growth. Net product ...

Patricia Carr, the SVP of $JAZZ, sold 1,140 shares of the company on 03-10-2025 for an estimated $157,103. We received data on the trade from a recent SEC filing ...

There are some "ifs, buts, and maybes" to consider in relation to this deal - if ONC201 is not approved in August, I'd expect to see Jazz stock take a palpable hit, but no biotech M&A deal will ...

Episode 3: Our Language As the stock market continues to soar, jazz is everywhere in America, and now, for the first time soloists and singers take center stage, transforming the music with their ...

HC Wainwright currently has a “Buy” rating and a $217.00 target price on the stock. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share.

JAZZ is a Zacks Rank #2 (Buy) stock, with a Value Style Score of A and VGM Score of A. Shares are currently trading at a forward P/E of 5.9X for the current fiscal year compared to the Medical ...